Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Merus (MRUS – Research Report) yesterday and set a price target of ...

Merus (NASDAQ:MRUS – Get Free Report) had its price target hoisted by research analysts at Citigroup from $89.00 to $97.00 in ...

We recently published a list of Jim Cramer’s Lightning Rounds: 12 Stocks Under the Spotlight. In this article, we are going ...

Needham & Company LLC reaffirmed their buy rating on shares of Merus (NASDAQ:MRUS – Free Report) in a report published on Monday,Benzinga reports. The firm currently has a $85.00 price target on the ...

Leerink Partners analyst Andrew Berens has maintained their bullish stance on MRUS stock, giving a Buy rating yesterday.Pick the best stocks ...

The two partners disclosed study results supporting an approval application for their drug dato-dxd. Elsewhere, Agenus cut ...

Meanwhile, in a bid to combat severe diseases, the FDA has green-lit Merus NV's cancer-targeting therapy Bizengri and ...

Bizengri (zenocutuzumab-zbco) as the first and only treatment indicated for adults with pancreatic adenocarcinoma or ...

Merus NV gained accelerated U.S. FDA approval of Bizengri (zenocutuzumab) as the first and only targeted therapy indicated for NRG1-positive pancreatic adenocarcinoma and non-small-cell lung cancer ...

The FDA has granted accelerated approval to zenocutuzumab, a new drug for adults with advanced non-small-cell lung cancer ...

President-elect Donald Trump hosted the chief executives of Pfizer, Eli Lilly and PhRMA at Mar-a-Lago for a dinner with ...

The biotech Merus received the first-ever FDA accelerated approval for a systemic treatment targeting a specific genetic ...